Montelukast Aurovitas (Montelukast)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1 on airway smooth muscle and inflammatory cells. This inhibition prevents leukotriene‑mediated bronchoconstriction, mucus production, and inflammation, thereby improving breathing and reducing allergic symptoms.

The appropriate dose of Montelukast Aurovitas is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and clinical response. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Montelukast in pregnancy and lactation are limited. The prescriber will weigh potential benefits against possible risks before recommending use. Women who are pregnant, planning pregnancy, or breastfeeding should discuss their situation with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who need additional control beyond inhaled therapy, though it is generally not a substitute for rescue inhalers.

Montelukast Aurovitas should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency.

Montelukast Aurovitas is taken orally as a tablet. The tablet should be swallowed whole with water, typically once daily, at the same time each day, unless the prescriber advises a different schedule.

Serious risks include neuropsychiatric events such as depression, agitation, or suicidal thoughts, as well as severe allergic reactions like rash, angioedema, or anaphylaxis. Liver injury and rare eosinophilic conditions have also been reported; patients should seek immediate medical attention if these occur.

Montelukast Aurovitas should be avoided in individuals with known hypersensitivity to montelukast or any component of the formulation. Caution is also advised for patients with a history of severe neuropsychiatric disorders or liver disease, and the drug should be used only under medical supervision in these cases.